Adrienne MacMillan, Chief Financial Officer and Founder
ANS-6637 is Phase-2 Ready for Addiction Disorder Clinical Development
ANS-6637 is the first-in-class compound that utilizes a novel pathway for the treatment of substance and behavior based addictions. ANS-6637, a highly selective ALDH2 Inhibitor with the potential to treat behavior and substance addictions based on a published mechanism of action that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine. In published preclinical studies, ANS-6637 reduced alcohol, cocaine and opiate craving. Phase-1 clinical trials of ANS-6637 in 97 human subjects demonstrated pharmacokinetics and a safety profile that support initiating Phase-2 clinical trials.
The Amygdala founders have deep and varied expertise in drug development, the addiction space and corporate considerations of public companies. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.
February 16, 2017 - Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences
GS-6637 utilizes a novel pathway for the potential treatment of substance and behavior based addictions
A Biopharmaceutical Company Focused on the Development and Commercialization of First-In-Class Drug Candidates for Addiction Disorders
Ivan Diamond, MD, PhD, Chief Science Officer and Founder
Peter Strumph, President and Chief Executive Officer and Founder
Lou Lange, MD, PhD, Executive Chairman and Founder